JO2289B1 - Exporters of NMDA compounds for the future - Google Patents

Exporters of NMDA compounds for the future

Info

Publication number
JO2289B1
JO2289B1 JO2001136A JOP20010136A JO2289B1 JO 2289 B1 JO2289 B1 JO 2289B1 JO 2001136 A JO2001136 A JO 2001136A JO P20010136 A JOP20010136 A JO P20010136A JO 2289 B1 JO2289 B1 JO 2289B1
Authority
JO
Jordan
Prior art keywords
nmda receptor
prdruge
receptor ligands
compounds
lower alkyl
Prior art date
Application number
JO2001136A
Other languages
Arabic (ar)
English (en)
Inventor
جاسشكه جورج
هويلر جورج
فيشر هولجر
الانين اليكساندر
بينارد ايمانويل
- باول هايتز ماري
باتلمان بيرند
Original Assignee
اف . هوفمان لاروش ايه جي
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by اف . هوفمان لاروش ايه جي filed Critical اف . هوفمان لاروش ايه جي
Application granted granted Critical
Publication of JO2289B1 publication Critical patent/JO2289B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JO2001136A 2000-08-21 2001-08-19 Exporters of NMDA compounds for the future JO2289B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00117918 2000-08-21

Publications (1)

Publication Number Publication Date
JO2289B1 true JO2289B1 (en) 2005-09-12

Family

ID=8169594

Family Applications (1)

Application Number Title Priority Date Filing Date
JO2001136A JO2289B1 (en) 2000-08-21 2001-08-19 Exporters of NMDA compounds for the future

Country Status (35)

Country Link
US (1) US6407235B1 (enExample)
EP (1) EP1313703B1 (enExample)
JP (1) JP4162991B2 (enExample)
KR (1) KR100589991B1 (enExample)
CN (1) CN1227230C (enExample)
AR (1) AR030373A1 (enExample)
AT (1) ATE386022T1 (enExample)
AU (2) AU8589401A (enExample)
BR (1) BR0113348A (enExample)
CA (1) CA2419279C (enExample)
CY (1) CY1107937T1 (enExample)
CZ (1) CZ303319B6 (enExample)
DE (1) DE60132782T2 (enExample)
DK (1) DK1313703T3 (enExample)
EC (1) ECSP034489A (enExample)
EG (1) EG24293A (enExample)
ES (1) ES2299508T3 (enExample)
HR (1) HRP20030125B1 (enExample)
HU (1) HU229802B1 (enExample)
IL (1) IL154254A0 (enExample)
JO (1) JO2289B1 (enExample)
MA (1) MA26947A1 (enExample)
MX (1) MXPA03001311A (enExample)
MY (1) MY136065A (enExample)
NO (1) NO324941B1 (enExample)
NZ (1) NZ523990A (enExample)
PA (1) PA8525601A1 (enExample)
PE (1) PE20020291A1 (enExample)
PL (1) PL204215B1 (enExample)
PT (1) PT1313703E (enExample)
RS (1) RS51467B (enExample)
RU (1) RU2272027C2 (enExample)
SI (1) SI1313703T1 (enExample)
WO (1) WO2002016321A1 (enExample)
ZA (1) ZA200300894B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001245891A1 (en) * 2000-03-21 2001-10-03 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
US6713490B2 (en) 2002-04-26 2004-03-30 Pfizer, Inc. 3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
WO2007072179A2 (en) * 2005-12-19 2007-06-28 Methylgene, Inc. Histone deacetylase inhibitors for enhancing activity of antifungal agents
WO2008074132A1 (en) 2006-12-19 2008-06-26 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
US8796330B2 (en) * 2006-12-19 2014-08-05 Methylgene Inc. Inhibitors of histone deacetylase and prodrugs thereof
RS58991B1 (sr) 2013-11-05 2019-08-30 Astrazeneca Ab Prolekovi nmda antagonista

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995020587A1 (en) * 1994-01-31 1995-08-03 Pfizer Inc. Neuroprotective chroman compounds
DE4410822A1 (de) 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW498067B (en) 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
TWI254043B (en) 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor

Also Published As

Publication number Publication date
SI1313703T1 (sl) 2008-06-30
CZ303319B6 (cs) 2012-08-01
EP1313703A1 (en) 2003-05-28
CY1107937T1 (el) 2013-09-04
KR20030022417A (ko) 2003-03-15
EG24293A (en) 2009-01-08
PL204215B1 (pl) 2009-12-31
DE60132782T2 (de) 2009-02-05
PT1313703E (pt) 2008-03-25
NO324941B1 (no) 2008-01-07
HU229802B1 (hu) 2014-07-28
CA2419279A1 (en) 2002-02-28
MY136065A (en) 2008-08-29
CN1227230C (zh) 2005-11-16
JP4162991B2 (ja) 2008-10-08
EP1313703B1 (en) 2008-02-13
DK1313703T3 (da) 2008-05-19
US6407235B1 (en) 2002-06-18
HK1059083A1 (en) 2004-06-18
HUP0301548A2 (hu) 2003-08-28
AR030373A1 (es) 2003-08-20
NO20030781D0 (no) 2003-02-19
CZ2003492A3 (cs) 2004-01-14
MXPA03001311A (es) 2003-06-30
ECSP034489A (es) 2003-03-31
HRP20030125A2 (en) 2005-02-28
JP2004506715A (ja) 2004-03-04
DE60132782D1 (de) 2008-03-27
ATE386022T1 (de) 2008-03-15
HRP20030125B1 (en) 2011-07-31
PA8525601A1 (es) 2002-04-25
YU13003A (sh) 2006-05-25
NO20030781L (no) 2003-02-19
AU2001285894B2 (en) 2006-06-15
ES2299508T3 (es) 2008-06-01
WO2002016321A1 (en) 2002-02-28
IL154254A0 (en) 2003-09-17
RU2272027C2 (ru) 2006-03-20
AU8589401A (en) 2002-03-04
US20020040037A1 (en) 2002-04-04
HUP0301548A3 (en) 2010-03-29
NZ523990A (en) 2004-09-24
PE20020291A1 (es) 2002-04-17
RS51467B (sr) 2011-04-30
BR0113348A (pt) 2003-07-08
CN1447793A (zh) 2003-10-08
ZA200300894B (en) 2004-04-30
PL361387A1 (en) 2004-10-04
KR100589991B1 (ko) 2006-06-15
MA26947A1 (fr) 2004-12-20
CA2419279C (en) 2008-10-14

Similar Documents

Publication Publication Date Title
ID17851A (id) Persenyawaan heterosiklis, produksi dan pemakaiannya
SE0104334D0 (sv) Therapeutic agents
DE69528437D1 (de) Substituierte azaindolylidenderivate und verfahren zu ihrer herstellung
IL150650A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
NZ331060A (en) Quinoxalinediones, preparation and pharmaceutical compositions thereof
GB9408185D0 (en) New benzamide derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
MXPA05010760A (es) Derivados de acido 2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)alquil fosfonico y su uso como antagonistas de receptor de n-metil-d-aspartato (nmda).
ES2187261A1 (es) Compuestos de eteres y amidas y su preparacion, como agentes anti-diabeticos.
PT1270570E (pt) Composto de amida e sua utilizacao
EP0359276A3 (en) Stabilized synthetic resin composition
IS6452A (is) Ný tetrahýdrópýridín, framleiðsluaðferð og lyfjasamsetningar sem innihalda þau
JO2289B1 (en) Exporters of NMDA compounds for the future
HRP20031055B1 (hr) Novi imunomodulirajući spojevi
PL362126A1 (en) New desloratadine salts, process for their synthesis and pharmaceutical compositions thereof
JO2433B1 (en) Preparation of heterocyclic lindane landscapes
IL156768A0 (en) Process for preparing (+/-) trans-4-p-fluorophenyl-3-hydroxymethyl-1-methylpiperidine
WO2002017954A1 (fr) Medicaments contre la maladie de parkinson
ATE6500T1 (de) 2-alpha-methyl-dopaminimino-6,7-dihydroxy-1,2,3 4-tetrahydronaphthalin, seine salze, und verfahren zu dessen herstellung.
MY133207A (en) Substituted benzolactam compaunds
IL150100A0 (en) Pharmaceutical compositions containing fused cyclic compounds
UA42798C2 (uk) Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, проміжні сполуки, фармацевтична композиція на основі аналогів 15-дезоксипергуаліну
DE69828037D1 (de) Pyrroloindol-derivate und zwischenprodukte zu ihrer herstellung